PCN132 Duration of Gefitinib Treatment in EGFR Mutation Positive NSCLC Patients in a UK Single Payement Access Scheme (SPA)
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.2172
https://www.valueinhealthjournal.com/article/S1098-3015(12)03886-7/fulltext
Title :
PCN132 Duration of Gefitinib Treatment in EGFR Mutation Positive NSCLC Patients in a UK Single Payement Access Scheme (SPA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03886-7&doi=10.1016/j.jval.2012.08.2172
First page :
A433
Section Title :
Cancer
Open access? :
No
Section Order :
823